# Digistain Laboratories

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/digistain-laboratories

- Industry: Healthcare Specialists
- Headquarters: Milton Keynes, UK
- Website: www.digistain.co.uk
- Total disclosed funding: $1M
- Latest round: Seed (Aug 3, 2022)
- Investors on record: 3

## About

Based in Buckinghamshire, UK, and founded in 2019 by CEO Dr. Hemmel Amrania and CSO Prof Chris Phillips, Digistain Limited doing business as Digistain Laboratories operates as a breast cancer diagnostics company developed machine learning-based technology for delivering treatment decision-making data for physicians and patients. In August 2022, Digistain Laboratories raised EUR 0.97 million in seed funding from Gaingels Syndicate and Sofia Angels Ventures, with participation from investor Y Combinator.

Digistain Laboratories provide DIGISTAIN, which is an analytical technology for chemical analysis with artificial intelligence and deliver breast cancer treatment decision-making while reducing actionable treatment decision times. The company’s software reports breast cancer recurrence when treated with hormone therapy alone. In addition, the firm offers Digistain’s prognostic score, which is the optical scan of the tumor tissue to capture a unique spectral signature of the tumor and uses a machine learning (ML) process to compute a risk score. As of 2023, the company’s client base includes Imperial College Healthcare, Barts Cancer Institute, and Nottingham University Hospitals.

## Funding rounds

- Seed, Aug 3, 2022, $1M — Y Combinator, Gaingels, Sofia Angels Ventures

## Investors

- Y Combinator (https://capitalatlas.ai/funds/y-combinator) — Seed
- Gaingels (https://capitalatlas.ai/funds/gaingels) — Seed
- Sofia Angels Ventures (https://capitalatlas.ai/funds/sofia-angels-ventures) — Seed